Neoadjuvant chemotherapy for osteosarcoma of the extremity: Long-term results of the Rizzoli's 4th protocol

G. Bacci, A. Briccoli, S. Ferrari, A. Longhi, M. Mercuri, R. Capanna, D. Donati, S. Lari, C. Forni, M. DePaolis

Research output: Contribution to journalArticlepeer-review

Abstract

From January 1993 to March 1995, 162 patients with osteosarcoma of extremities were treated according to the IOR/OS-4 protocol. 133 patients had localised disease, while 29 had metastases at diagnosis. These last patients were simultaneously operated upon for their primary and metastatic lesions. Chemotherapy consisted preoperatively of two cycles of high dose methotrexate (HDMTX) and one cycle each of cisplatin (CDP)-doxorubicin (ADM), CDP/ifosfamide (IFO) and IFO/ADM. After surgery, patients were treated with the afore mentioned drugs used as single agents. The mean follow-up of all patients was 6.5 years (5.5-8 years). Surgery was a limb salvage in 94% of cases, and the 5-year event-free survival (EFS) and overall survival (OS) rates were 56 and 71% for patients with localised disease, and 17 and 24% for patients with metastases at diagnosis. These results did not differ from those achieved in our previous study (IOR/OS-3) in which IFO was used only postoperatively in poor responders.

Original languageEnglish
Pages (from-to)2030-2039
Number of pages10
JournalEuropean Journal of Cancer
Volume37
Issue number16
DOIs
Publication statusPublished - 2001

Keywords

  • Limb salvage
  • Lung metastases
  • Metastasectomy
  • Neoadjuvant chemotherapy
  • Osteosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Neoadjuvant chemotherapy for osteosarcoma of the extremity: Long-term results of the Rizzoli's 4th protocol'. Together they form a unique fingerprint.

Cite this